335 related articles for article (PubMed ID: 18394616)
1. Premature luteinization and in vitro fertilization outcome in gonadotropin/gonadotropin-releasing hormone antagonist cycles in women with polycystic ovary syndrome.
Segal S; Glatstein I; McShane P; Hotamisligil S; Ezcurra D; Carson R
Fertil Steril; 2009 May; 91(5):1755-9. PubMed ID: 18394616
[TBL] [Abstract][Full Text] [Related]
2. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
[TBL] [Abstract][Full Text] [Related]
3. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
[TBL] [Abstract][Full Text] [Related]
5. Progesterone levels on the hCG day and outcomes in vitro fertilization in women with polycystic ovary syndrome.
Peng C; Guo Z; Long X; Lu G
J Assist Reprod Genet; 2012 Jul; 29(7):603-7. PubMed ID: 22552733
[TBL] [Abstract][Full Text] [Related]
6. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin releasing hormone agonist protocol.
Lai TH; Lee FK; Lin TK; Horng SG; Chen SC; Chen YH; Wang PC
Fertil Steril; 2009 Aug; 92(2):508-14. PubMed ID: 18701101
[TBL] [Abstract][Full Text] [Related]
7. [Oocyte and embryo quality and outcome of ICSI cycles in patients with polycystic ovary syndrome (PCOS) versus normo-ovulatory].
Kdous M; Chaker A; Zhioua A; Zhioua F
J Gynecol Obstet Biol Reprod (Paris); 2009 Apr; 38(2):133-43. PubMed ID: 19179017
[TBL] [Abstract][Full Text] [Related]
8. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
9. Effects of pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome.
Kim CH; Jeon GH; Kim SR; Kim SH; Chae HD; Kang BM
Fertil Steril; 2010 Jun; 94(1):236-41. PubMed ID: 19324344
[TBL] [Abstract][Full Text] [Related]
10. Outcome of intracytoplasmic sperm injection in patients with polycystic ovary syndrome or isolated polycystic ovaries.
Esinler I; Bayar U; Bozdag G; Yarali H
Fertil Steril; 2005 Oct; 84(4):932-7. PubMed ID: 16213846
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
Kumbak B; Kahraman S
Acta Obstet Gynecol Scand; 2009; 88(5):563-8. PubMed ID: 19306135
[TBL] [Abstract][Full Text] [Related]
12. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
[TBL] [Abstract][Full Text] [Related]
13. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
Kolibianakis EM; Papanikolaou EG; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
Fertil Steril; 2007 Nov; 88(5):1382-8. PubMed ID: 17445806
[TBL] [Abstract][Full Text] [Related]
14. Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are influenced by body mass index.
McCormick B; Thomas M; Maxwell R; Williams D; Aubuchon M
Fertil Steril; 2008 Dec; 90(6):2304-9. PubMed ID: 18191852
[TBL] [Abstract][Full Text] [Related]
15. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
Papaleo E; Unfer V; Baillargeon JP; Fusi F; Occhi F; De Santis L
Fertil Steril; 2009 May; 91(5):1750-4. PubMed ID: 18462730
[TBL] [Abstract][Full Text] [Related]
16. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
Ge HS; Huang XF; Zhang W; Zhao JZ; Lin JJ; Zhou W
Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
[TBL] [Abstract][Full Text] [Related]
17. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
[TBL] [Abstract][Full Text] [Related]
20. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
